EGRX (Eagle Pharmaceuticals) Total Assets: $404.8 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EGRX Eagle Pharmaceuticals Inc EGRX
16 GF Score
Price $0.75
View Full Analysis

What is Eagle Pharmaceuticals Total Assets?

Eagle Pharmaceuticals EGRX 16 Total Assets is $404.8 Mil as of Jun. 2023. GuruFocus rates EGRX with a GF Score™ of 16/100.

Eagle Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2023 was $404.8 Mil.

Total Assets is connected with ROA %. Eagle Pharmaceuticals's annualized ROA % for the quarter that ended in Jun. 2023 was 5.04%. Total Assets is also linked to Revenue through Asset Turnover. Eagle Pharmaceuticals's Asset Turnover for the quarter that ended in Jun. 2023 was 0.16.

Eagle Pharmaceuticals  (OTCPK:EGRX) Total Assets Explanation

Total Assets is connected with ROA %.

Eagle Pharmaceuticals's annualized ROA % for the quarter that ended in Jun. 2023 is

ROA %=Net Income (Q: Jun. 2023 )/( (Total Assets (Q: Mar. 2023 )+Total Assets (Q: Jun. 2023 ))/ count )
=20.656/( (414.175+404.822)/ 2 )
=20.656/409.4985
=5.04 %

Note: The Net Income data used here is four times the quarterly (Jun. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Eagle Pharmaceuticals's Asset Turnover for the quarter that ended in Jun. 2023 is

Asset Turnover
=Revenue (Q: Jun. 2023 )/( (Total Assets (Q: Mar. 2023 )+Total Assets (Q: Jun. 2023 ))/ count )
=64.646/( (414.175+404.822)/ 2 )
=64.646/409.4985
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Eagle Pharmaceuticals Total Assets Related Terms

Eagle Pharmaceuticals Total Assets Historical Data

* Premium members only.

The historical data trend for Eagle Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eagle Pharmaceuticals Total Assets Chart

Eagle Pharmaceuticals Annual Data
Trend Sep13 Sep14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 238.60 254.55 253.19 253.73 406.16

Eagle Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 381.76 386.45 406.16 414.18 404.82
EGRX
16GF Score
Eagle Pharmaceuticals Inc EGRX
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eagle Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Eagle Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets=Total Equity (A: Dec. 2022 )+Total Liabilities (A: Dec. 2022 )
=233.56+172.6
=406.2

Eagle Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2023 is calculated as

Total Assets=Total Equity (Q: Jun. 2023 )+Total Liabilities (Q: Jun. 2023 )
=252.04+152.782
=404.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $404.8 Mil mean?
Eagle Pharmaceuticals (EGRX) has a Total Assets of $404.8 Mil as of Jun. 2023. The total amount of assets as recorded on a company's balance sheet. View historical data on Eagle Pharmaceuticals and its competitors.
Is Eagle Pharmaceuticals' Total Assets too high?
Eagle Pharmaceuticals' current Total Assets is $404.8 Mil. Overall, Eagle Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Eagle Pharmaceuticals' Total Assets compare to IXHL and RMTI?
Eagle Pharmaceuticals' Total Assets of $404.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Eagle Pharmaceuticals and its competitors. Eagle Pharmaceuticals's current Total Assets is $404.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eagle Pharmaceuticals stock overvalued right now?
Eagle Pharmaceuticals (EGRX) has a current Total Assets of $404.8 Mil. The current Total Assets is $404.8 Mil. Eagle Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Eagle Pharmaceuticals (EGRX), the current Total Assets is $404.8 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eagle Pharmaceuticals Business Description

Address 50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ, USA, 07677
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advance stages of development and is under review for approval by the Food and Drug Administration.
16GF Score

Get the complete analysis for EGRX

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.75
Price